325806-69-7

Basic information

• Product Name: N-(4-chlorophenyl)-3,5-dinitrobenzamide
• Synonyms: N-(4-chlorophenyl)-3,5-dinitrobenzamide
• CAS NO: 325806-69-7
• Molecular Formula: C₁₃H₈ClN₃O₅
• Molecular Weight: 321.67
• Mol File: 325806-69-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(4-chlorophenyl)-3,5-dinitrobenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-chlorophenyl)-3,5-dinitrobenzamide(325806-69-7)
• EPA Substance Registry System: N-(4-chlorophenyl)-3,5-dinitrobenzamide(325806-69-7)

Safety Data

• Hazardous Substances Data: 325806-69-7(Hazardous Substances Data)

Upstream product

• 106-47-8 4-chloro-aniline 
• 99-33-2 3,5-dinitrobenoyl chloride 
• 99-34-3 3,5-dinitrobenzoic acid 

Downstream Products

• 860604-85-9 3,5-dinitro-benzoic acid-(4-chloro-2,6-dinitro-anilide) 
• 5388-62-5 4-chloro-2,6-dinitroaniline 

Relevant articles and documents

Design, Synthesis and in Vitro Tumor Cytotoxicity Evaluation of 3,5-Diamino-N-substituted Benzamide Derivatives as Novel GSK-3β Small Molecule Inhibitors

Glycogen synthase kinase-3 (GSK-3) plays an important regulatory role in various signaling pathways; such as PI3 K/AKT, which is closely related to the occurrence and development of tumors. At present, the most reported active GSK-3 inhibitors have the same structure: lactam ring or amide structure. To find out the GSK-3β small molecule inhibitor with novel, safe, efficient and more uncomplicated synthesis method, we analyzed in-depth reported crystal-binding patterns of GSK-3β small molecule inhibitor with GSK-3β protein, and designed and synthesized 17 non-reported 3,5-diamino-N-substituted benzamide compounds. Their structures were confirmed by 1H-NMR, 13C-NMR, and HR-MS. The preliminary screening of tumor cytotoxicity of compounds in vitro was detected by MTT, and their structure–activity relationships were illustrated. The results have shown that 3,5-diamino-N-[3-(trifluoromethyl)phenyl]benzamide (4d) exhibited significant tumor cytotoxicity against human colon cancer cells (HCT-116) with IC50 of 8.3 μm and showed commendable selectivity to GSK-3β. In addition, Compound 4d induced apoptosis to some extent and possessed modest PK properties.